Medartis Holding AG

SWX:MED Stock Report

Market Cap: CHF 904.1m

Medartis Holding Valuation

Is MED undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MED when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

CHF 76.66
Fair Value
5.0% undervalued intrinsic discount
3
Number of Analysts

Below Fair Value: MED (CHF72.8) is trading below our estimate of fair value (CHF76.66)

Significantly Below Fair Value: MED is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MED?

Key metric: As MED is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MED. This is calculated by dividing MED's market cap by their current revenue.
What is MED's PS Ratio?
PS Ratio3.8x
SalesCHF 236.34m
Market CapCHF 904.07m

Price to Sales Ratio vs Peers

How does MED's PS Ratio compare to its peers?

The above table shows the PS ratio for MED vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.6x
MEDX medmix
0.7x3.54%CHF 348.2m
MOVE Medacta Group
5x11.14%CHF 3.0b
METN Metall Zug
1.7x4.83%CHF 332.1m
SOON Sonova Holding
3.1x5.51%CHF 11.9b
MED Medartis Holding
3.8x16.43%CHF 904.1m

Price-To-Sales vs Peers: MED is expensive based on its Price-To-Sales Ratio (3.8x) compared to the peer average (2.6x).

Price to Sales Ratio vs Industry

How does MED's PS Ratio compare vs other companies in the European Medical Equipment Industry?

44 CompaniesPrice / SalesEstimated GrowthMarket Cap
MED 3.8xIndustry Avg. 3.3xNo. of Companies44PS03.67.210.814.418+
44 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MED is expensive based on its Price-To-Sales Ratio (3.8x) compared to the European Medical Equipment industry average (3.3x).

Price to Sales Ratio vs Fair Ratio

What is MED's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MED PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.8x
Fair PS Ratio6.1x

Price-To-Sales vs Fair Ratio: MED is good value based on its Price-To-Sales Ratio (3.8x) compared to the estimated Fair Price-To-Sales Ratio (6.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MED forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 72.80
CHF 92.30
+26.79%
5.71%CHF 98.90CHF 86.00n/a3
Nov ’26CHF 81.50
CHF 92.30
+13.25%
5.71%CHF 98.90CHF 86.00n/a3
Oct ’26CHF 86.10
CHF 92.30
+7.20%
5.71%CHF 98.90CHF 86.00n/a3
Sep ’26CHF 92.50
CHF 92.30
-0.22%
5.71%CHF 98.90CHF 86.00n/a3
Aug ’26CHF 86.40
CHF 89.47
+3.55%
2.95%CHF 92.40CHF 86.00n/a3
Jul ’26CHF 78.30
CHF 89.20
+13.92%
3.59%CHF 92.40CHF 86.00n/a2
Jun ’26CHF 79.50
CHF 89.20
+12.20%
3.59%CHF 92.40CHF 86.00n/a2
May ’26CHF 76.80
CHF 91.13
+18.66%
4.15%CHF 95.00CHF 86.00n/a3
Apr ’26CHF 73.10
CHF 91.13
+24.67%
4.15%CHF 95.00CHF 86.00n/a3
Mar ’26CHF 73.90
CHF 91.13
+23.32%
4.15%CHF 95.00CHF 86.00n/a3
Feb ’26CHF 69.50
CHF 102.47
+47.43%
7.23%CHF 110.00CHF 92.40n/a3
Jan ’26CHF 56.60
CHF 102.47
+81.04%
7.23%CHF 110.00CHF 92.40n/a3
Dec ’25CHF 56.00
CHF 102.47
+82.98%
7.23%CHF 110.00CHF 92.40n/a3
Nov ’25CHF 56.20
CHF 98.20
+74.73%
9.96%CHF 110.00CHF 85.40CHF 81.504
Oct ’25CHF 57.20
CHF 98.20
+71.68%
9.96%CHF 110.00CHF 85.40CHF 86.104
Sep ’25CHF 63.50
CHF 98.20
+54.65%
9.96%CHF 110.00CHF 85.40CHF 92.504
Aug ’25CHF 75.00
CHF 98.98
+31.97%
9.51%CHF 110.00CHF 85.40CHF 86.404
Jul ’25CHF 68.40
CHF 98.98
+44.70%
9.51%CHF 110.00CHF 85.40CHF 78.304
Jun ’25CHF 76.50
CHF 98.98
+29.38%
9.51%CHF 110.00CHF 85.40CHF 79.504
May ’25CHF 80.20
CHF 98.98
+23.41%
9.51%CHF 110.00CHF 85.40CHF 76.804
Apr ’25CHF 89.40
CHF 98.85
+10.57%
9.70%CHF 110.00CHF 84.90CHF 73.104
Mar ’25CHF 72.70
CHF 96.78
+33.12%
11.65%CHF 110.00CHF 81.80CHF 73.904
Feb ’25CHF 73.90
CHF 101.77
+37.71%
8.22%CHF 110.00CHF 90.30CHF 69.503
Jan ’25CHF 84.00
CHF 101.77
+21.15%
8.22%CHF 110.00CHF 90.30CHF 56.603
Dec ’24CHF 73.20
CHF 101.77
+39.03%
8.22%CHF 110.00CHF 90.30CHF 56.003
Nov ’24CHF 71.40
CHF 101.77
+42.53%
8.22%CHF 110.00CHF 90.30CHF 56.203
CHF 92.3
Fair Value
21.1% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/17 02:05
End of Day Share Price 2025/11/17 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medartis Holding AG is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullResearch Partners AG
Alexander BurganskyResearch Partners AG
null nullStifel, Equities Research